Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, PR China.
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, PR China; State Key Laboratory of Coordination Chemistry, Nanjing University, Nanjing 210023, PR China.
Pharmacol Res. 2023 Jan;187:106556. doi: 10.1016/j.phrs.2022.106556. Epub 2022 Nov 17.
Traditional platinum-based anticancer drugs, led by cisplatin, play an important role in chemotherapy. However, the development of platinum compounds is limited due to serious toxicity and side effects. In recent years, studies have showed that immunogenic cell death (ICD) may be one of the potential action mechanisms of classical platinum drugs, such as oxaliplatin. This strategy combining chemotherapy and immunotherapy can effectively utilize the body's immune system to help platinum compounds to fight against tumors, and the dose can be appropriately reduced to limit toxic side effects. The induction of ICD by platinum compounds has become a research hotspot and one of the future development directions of metal drugs. Here, the progress of platinum compounds were collected and comprehensively summarized, their capacity of ICD induction and mechanism of action are exposed, providing reference for the design and synthesis of new anticancer platinum ICD inducers.
传统的以顺铂为代表的铂类抗癌药物在化疗中发挥着重要作用。然而，由于严重的毒性和副作用，铂类化合物的发展受到限制。近年来，研究表明免疫原性细胞死亡（ICD）可能是经典铂类药物（如奥沙利铂）的潜在作用机制之一。这种化疗与免疫治疗相结合的策略可以有效地利用机体的免疫系统来帮助铂类化合物对抗肿瘤，同时可以适当减少剂量以限制毒性副作用。铂类化合物诱导 ICD 已成为研究热点和金属药物未来发展方向之一。本文收集并综合总结了铂类化合物的研究进展，揭示了其诱导 ICD 的能力和作用机制，为设计和合成新型抗癌铂类 ICD 诱导剂提供了参考。
